ARS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.26 USD | -2.82% |
|
-8.83% | +50.73% |
| Apr. 18 | ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing | MT |
| Apr. 18 | ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | 5.54M | Sales 2025 * | 85.45M | Capitalization | 820M |
|---|---|---|---|---|---|
| Net income 2024 * | -59M | Net income 2025 * | -35M | EV / Sales 2024 * | 122 x |
| Net cash position 2024 * | 141M | Net cash position 2025 * | 144M | EV / Sales 2025 * | 7.91 x |
| P/E ratio 2024 * |
-13.5
x | P/E ratio 2025 * |
-24.1
x | Employees | 25 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.55% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.82% | ||
| 1 week | -10.02% | ||
| Current month | -19.18% | ||
| 1 month | -4.51% | ||
| 3 months | +22.01% | ||
| 6 months | +142.23% | ||
| Current year | +50.73% |
1 week
8.15
9.19
1 month
8.1511.27
Current year
5.1911.27
1 year
2.5511.27
3 years
2.5511.27
5 years
2.5511.27
10 years
2.5511.27
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 8.26 | -2.82% | 334,679 |
| 24-04-23 | 8.5 | +3.53% | 510,439 |
| 24-04-22 | 8.21 | -3.07% | 394,656 |
| 24-04-19 | 8.47 | +0.36% | 487,875 |
| 24-04-18 | 8.44 | -6.84% | 918,109 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.5
USD
Average target price
19
USD
Spread / Average Target
+123.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +50.73% | 820M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- SPRY Stock
